Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
information fournie par Boursorama CP 06/03/2024 à 07:30

Poster presentation of new data
from ongoing randomized Phase I trial targeting head and neck cancers



Strasbourg, France, March 6, 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster on updated data from the ongoing randomized Phase I trial of TG4050 at the American Association for Cancer Research Annual Meeting (AACR). The AACR will take place in San Diego, California, USA, from April 5 to 10, 2024.
.../...

The abstract will be available on the AACR website April 5, 2024, at 3:00 p.m. ET / 9:00 p.m. CET.

.../...

Valeurs associées

TRANSGENE
0,8090 EUR Euronext Paris -0,86%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
ABIVAX
77,6 -30,59%
SOITEC
153,7 +4,42%
CAC 40
8 202,06 +0,68%
Pétrole Brent
93,89 -1,43%
HAFFNER ENERGY
0,3315 +1,38%
Chargement...

Pages les plus populaires

L'offre BoursoBank